Canada markets open in 53 minutes

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.7100-0.0300 (-1.09%)
At close: 04:00PM EDT
2.8000 +0.09 (+3.32%)
After hours: 07:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.7400
Open2.8500
Bid2.6500 x 100
Ask2.8000 x 100
Day's Range2.5100 - 2.9000
52 Week Range2.5000 - 46.0000
Volume50,153
Avg. Volume81,907
Market Cap5.177M
Beta (5Y Monthly)-0.57
PE Ratio (TTM)N/A
EPS (TTM)-24.4000
Earnings DateMar 31, 2024 - Apr 05, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est165.00
  • PR Newswire

    Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the closing on March 21, 2024 of its previously announced registered direct offering priced at-the-market under the Nasdaq rules for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the Company and warrants to purchase up to 1,542,112 shares of commo

  • PR Newswire

    Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered into definitive agreements for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the Company and warrants to purchase up to 1,542,112 shares of common stock at a combined offering price of $4.215 per share of common stock (or per p

  • PR Newswire

    Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

    Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Korean Patent Office has issued a Notice of Patent Grant for a broad patent that covers the use of Genprex's lead drug candidate, Reqorsa® Immunogene Therapy, in combination with anti-PD-1 and PD-L1 antibodies through 2037.